GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » Debt-to-EBITDA

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Debt-to-EBITDA : 2.11 (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tribute Pharmaceuticals Canada's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $14.59 Mil. Tribute Pharmaceuticals Canada's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $11.36 Mil. Tribute Pharmaceuticals Canada's annualized EBITDA for the quarter that ended in Sep. 2015 was $12.28 Mil. Tribute Pharmaceuticals Canada's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 was 2.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Tribute Pharmaceuticals Canada's Debt-to-EBITDA or its related term are showing as below:

TBUFF's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful Debt-to-EBITDA only.

Tribute Pharmaceuticals Canada Debt-to-EBITDA Historical Data

The historical data trend for Tribute Pharmaceuticals Canada's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tribute Pharmaceuticals Canada Debt-to-EBITDA Chart

Tribute Pharmaceuticals Canada Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.87 -1.15 -5.83

Tribute Pharmaceuticals Canada Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 15.63 -1.07 -1.16 2.11

Competitive Comparison of Tribute Pharmaceuticals Canada's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tribute Pharmaceuticals Canada's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Tribute Pharmaceuticals Canada's Debt-to-EBITDA falls into.



Tribute Pharmaceuticals Canada Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tribute Pharmaceuticals Canada's Debt-to-EBITDA for the fiscal year that ended in Dec. 2014 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.144 + 12.112) / -2.275
=-5.83

Tribute Pharmaceuticals Canada's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(14.588 + 11.358) / 12.28
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2015) EBITDA data.


Tribute Pharmaceuticals Canada  (OTCPK:TBUFF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Tribute Pharmaceuticals Canada Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Traded in Other Exchanges
N/A
Address
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Executives
John M Gregory director, 10 percent owner
Sj Strategic Investments Llc 10 percent owner
Joan P Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory other: Member 340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines